Zealand announces full year results in line with guidance and release of its Annual Report for 2015
|
|
- Jeffrey Perkins
- 5 years ago
- Views:
Transcription
1 Company announcement No. 5 / 2016 Zealand announces full year results in line with guidance and release of its Annual Report for was a transitional year for Zealand with considerable business and pipeline advancements and a clear strategic direction set for accelerated value creation Strong Q4 with revenue of DKK 167 million / EUR 22 million and a net result of DKK 70 million / EUR 9 million Full year net result of DKK -114 million / EUR -15 million (2014: DKK -65 million / EUR -9 million) with revenues of DKK 188 million / EUR 25 million (2014: DKK 154 million / EUR 21 million) in line with guidance End 2015 cash position of DKK 440 million / EUR 59 million (2014: DKK 538 million / EUR 72 million), excluding the milestone of DKK 137 million / EUR 18 million from Sanofi in December, which was paid only in January 2016 Key business events in Q and the period thereafter: - The fixed-ratio combination of lixisenatide and Lantus (LixiLan) was submitted for US registration with use of a priority review voucher by Sanofi, triggering a USD 20 million payment to Zealand. FDA accepted the file in February An FDA Advisory Committee Meeting on lixisenatide and the fixed-ratio combination of lixisenatide and Lantus has been scheduled for May Patient enrolment completed in Phase IIb trial with elsiglutide by Helsinn - Two new lead drug candidates advanced into preclinical development under collaborations with Boehringer Ingelheim: One in October 2015 with an associated EUR 3 million payment to Zealand, and one in February Two proprietary medicines have advanced into Phase II: ZP4207 for severe hypoglycemia and ZP1848 for short bowel syndrome - Results from well-conducted Phase II Proof-of-Concept trial showed no effect of danegaptide on reducing cardiac reperfusion injuries - Appointment of Andrew Parker as new Senior Vice President and Chief Science Officer with effect from 1 July 2016 Copenhagen, 16 March 2016 Zealand Pharma A/S ( Zealand ) (CVR no ) announces financial results in line with guidance and considerable progress for its product portfolio and business for the twelve month period from 1 January to 31 December Zealand Pharma A/S 1/8
2 Commenting on Zealand s full year results and the Annual Report for 2015, Britt Meelby Jensen, President and CEO of Zealand, said: 2015 was one of the best years in the history of Zealand. Financial results were as expected with considerable financing from milestone payments, and our business and portfolio have substantially progressed. Under our agreement with Sanofi, both lixisenatide and LixiLan have been filed for approvals in the US with regulatory decisions expected in July and August, respectively. These milestones are decisive for the prospects of Zealand becoming a profitable company near term. We have also advanced and expanded our own proprietary pipeline, including the initiation of Phase II trials with two new lead drug candidates, a glucagon analogue for hypoglycemia and a GLP-2 analogue for short bowel syndrome. These advancements support our new strategy for accelerated value creation, in that we will take select specialty peptide medicines all the way through registration ourselves and thereby retain more value and control for the benefit of both patients and our shareholders. And she continued: As we expand and invest more in advancing our own investigational medicines, we will obviously increase our operating expenses. We remain mindful that this increase will largely be offset by growing royalty revenue and that Zealand retains a solid cash position. We have had a great start to 2016 and it is with confidence that I look further into another exciting year with a strong news flow and further growth of our business. Financial highlights for 2015 Revenue of DKK / EUR 25.2 million (2014: DKK / EUR 20.7 million). Royalty expenses of DKK 22.3 / EUR 3.0 million (2014: DKK 13.8 / EUR 1.9 million). Net operating expenses of DKK / EUR 33.1 million (2014: DKK / EUR 28.7 million). Net result of DKK / EUR million (2014: DKK / EUR -8.7 million). Cash and securities amounted to DKK / EUR 59.0 million at 31 December 2015 (2014: DKK / EUR 72.3 million). Financial highlights for Q Revenue of DKK / EUR 22.4 million (Q4 2014: DKK 6.3 / EUR 0.8 million). Net operating expenses of DKK 70.6 / EUR 9.5 million (Q4 2014: DKK 73.4 / EUR 9.9 million). Net result of DKK 69.7 / EUR 9.4 million (Q4 2014: DKK / EUR 8.5 million). Business highlights and updates for Q and the period thereafter Maturing portfolio of out-licensed products and projects Lixisenatide for Type 2 diabetes (license collaboration with Sanofi) Marketed as Lyxumia outside the US / under regulatory review in the US Royalty revenue to Zealand on Sanofi s sales of Lyxumia outside the US amounted to DKK 28.6 million / EUR 3.8 million in 2015, an increase of 41% over Royalty revenue for Q4 was DKK 8.1 million / EUR 1.1 million, an increase of 31% compared to the same period in The main contributing countries were the UK, Spain, Italy and Japan. Zealand Pharma A/S 2/8
3 In the US, lixisenatide is under FDA review and a regulatory decision is expected in July On 15 March 2016, FDA announced that an Advisory Committee meeting on lixisenatide and on the fixed-ratio combination of lixisenatide and Lantus has been scheduled for May Fixed-ratio combination of lixisenatide and Lantus (LixiLan) for Type 2 diabetes (license collaboration with Sanofi) Under regulatory priority review in the US with EU submission expected before end March 2016 End December 2015, based on positive top-line results reported in Q from two pivotal Phase III trials (LixiLan-L and LixiLan-O), Sanofi submitted the combination of lixisenatide and Lantus for US registration, redeeming a Priority Review Voucher as part of the filing. Triggered by this milestone was a USD 20 million payment to Zealand. End February 2016, FDA accepted the file for priority review of the combination product with a regulatory decision in the US expected in August On 15 March 2016, FDA announced that an Advisory Committee meeting on the fixed-ratio combination of lixisenatide and insulin glargine (Lantus ) has been scheduled for May Sanofi plans to submit the combination product for regulatory approval in the EU before end March Elsiglutide for chemotherapy-induced diarrhea (license collaboration with Helsinn) Completing Phase IIb development In February 2016, Helsinn completed the enrolment of approximately 500 patients with colorectal cancer into its Phase IIb dose-finding trial. The trial was initiated in February 2015 and evaluates the effect and safety of three doses of elsiglutide as a novel and potential first-ever treatment of chemotherapy induced diarrhea. The Phase II trial will complete later in H with top-line results expected in H Progress under both Boehringer Ingelheim license collaborations in diabetes and obesity In October 2015, Boehringer Ingelheim selected and advanced a novel, undisclosed peptide therapeutic into preclinical development as a potential new treatment of obesity or diabetes under one of two ongoing collaborations. This development milestone led to a EUR 3 million payment to Zealand. Under the other collaboration between Zealand and Boehringer Ingelheim, covering novel glucagon/glp-1 dual acting agonists for the treatment of Type 2 diabetes and/or obesity, Boehringer in February 2016 selected and advanced a new lead drug candidate into preclinical development. Growing proprietary pipeline (Zealand retains all rights) ZP4207 (single-dose) rescue treatment for acute, severe hypoglycemia in diabetes In clinical Phase II development In February 2016, Zealand initiated dosing of patients in a Phase II trial with ZP4207 for the treatment and management of hypoglycemia in diabetes. Contrary to existing products, which are Zealand Pharma A/S 3/8
4 based on native glucagon, ZP4207 has high stability in liquid formulation and potential as a ready-touse rescue treatment. The Phase II trial is planned to enroll 56 patients with Type 1 diabetes and results will be an important step in the dual product development plans for ZP4207: as a more convenient rescue treatment for severe hypoglycaemia associated with insulin therapy in diabetes and for multiple-dose use as an essential component in a dual-hormone artificial pancreas system. Completion of the Phase II trial and results are expected in H ZP1848 (long-acting GLP-2 analogue) for short bowel syndrome In clinical Phase II development In February 2016, Zealand successfully dosed the first patients with short bowel syndrome in a clinical Phase II Proof-of-Concept trial with ZP1848. Short bowel syndrome is a serious and most often chronic specialty disease caused by reduced or loss of intestinal function and a huge burden on patients. The ongoing Phase II trial is planned to enroll 18 patients with short bowel syndrome, who will all be randomized to two of three different doses of ZP1848 in a cross-over design. Updates on patient enrolment and timelines for trial completion will be communicated in H Currently, Phase II results are expected to be available in H ZP4207 (multiple-dose) for better hypoglycemia control and glucose management In preparation for next clinical step after Phase Ib Zealand has evaluated ZP4207 also in a Phase Ib trial with results showing good safety and tolerability after multiple ascending dosing of this soluble and stable glucagon analogue. A multiple-dose version of ZP4207 has particular potential as an essential component in a dualhormone artificial pancreas device for better hypoglycaemia control and derived beneficial effect on long-term glucose management. Zealand is evaluating several options and is preparing for the advancement of ZP4207 for multipledose use into the next clinical phase. Danegaptide for cardiac reperfusion injuries Clinical Phase II Proof-of-Concept trial completed with negative results In March 2016, Zealand completed a clinical Phase II Prof-of-Concept trial for the evaluation of danegaptide as a potential first-ever pharmaceutical treatment of cardiac reperfusion injuries. The trial was well-conducted, delivering a high-quality data set with results however, showing no effect of danegaptide on the primary endpoint of saving cardiac tissue from ischemic reperfusion injuries as measured on the Myocardial Salvage Index (MSI). Other business events New competencies added to senior management Two internationally experienced profiles have been appointed to complement the competence span of Zealand s senior management team: Zealand Pharma A/S 4/8
5 On 1 December 2015, Carlos de Sousa joined Zealand as Senior Vice President and Chief Business Officer. Carlos has 25 years of experience from numerous senior leadership positions in the international pharmaceutical and biotech industries. Recently, Andrew Parker has been appointed as Senior Vice President and Chief Science Officer with effect as of 1 July 2017 the latest. Andrew has more than 20 years of experience from senior leadership and managerial positions in international pharmaceutical, biotech and start-up companies, including several years with Shire Pharmaceuticals, Opsona Therapeutics, and AstraZeneca. He holds a Ph.D. from the National Institute for Medical Research at Mill Hill, London, conducted post-doctoral research at Johns Hopkins Medical School, Baltimore, USA, and also has an MBA from the University of Warwick Business School, UK. Collaboration with BioSolveIT to create unique, new peptide drug discovery software Zealand has joined forces with BioSolveIT, a renowned medicinal chemistry informatics company, in the creation of a novel, unique software tool tailored to advance the design and development of therapeutic peptides. A first version of the software, called PepSee, has been implemented at Zealand and already demonstrated its ability to accelerate and add new dimensions to peptide design. Completion of a second version is expected within 18 months, adding additional features, and with the potential to support innovation and push the boundaries of peptide research. Financial guidance for 2016 In 2016, Zealand expects continuously growing royalty payments from Sanofi on sales of Lyxumia outside the US. Pending positive US regulatory decisions on both lixisenatide and LixiLan in Q and potential subsequent commercial launches by Sanofi also in 2016, royalty payments on US sales may be received as well. However, no specific guidance on the level of royalties can be provided, as Sanofi has given no guidance on 2016 sales of Lyxumia or LixiLan. Additional revenue of up to DKK 200 million / EUR 27 million may be received from event driven partner related milestones. Net operating expenses in 2016 are expected to increase to a range of DKK million / EUR million. The increase compared to 2015 relates to a higher level of clinical development costs associated with the advancement of Zealand s proprietary clinical pipeline. Operating loss before royalty income/expenses is therefore expected at a range of DKK / EUR million. Zealand s Annual Report 2015 This full year announcement should be read in conjunction with Zealand s Annual Report for 2015, published today and attached to the announcement in a PDF-version. Following publication, a PDF version of the Annual Report can also be accessed and downloaded from the front page of Zealand s website or directly from the following link: ( Under the same link, there will also be access to video recordings with members of senior management presenting on different part of Zealand s business and outlook. Zealand Pharma A/S 5/8
6 Printed versions of the Annual Report 2015 will be available from the beginning of April and a copy can be requested by contacting Zealand at info@zealandpharma.com or investors@zealandpharma.com. The full report is only available in English, however a Danish version of the Management Review will be available both as PDF and in print before the company s Annual General Meeting on 19 April Conference call with Zealand s management today at 14:00 CET / 9:00 EDT Zealand s management will host a conference call today at 14:00 CET/ 9:00 EDT to present the Full Year results and the Annual Report for Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, Senior Vice President and Chief Financial Officer, Adam Steensberg, Chief Medical and Development Officer and Hanne Leth Hillman, Senior Vice President and Head of IR and Communications. The presentation will be followed by a Q&A session. The conference call will be conducted in English and the dial-in numbers are: DK standard access UK and international +44 (0) US (free dial-in) A live audio webcast of the call including an accompanying slide presentation will be available via the following link, accessible also from the Investor section of Zealand s website ( Participants are advised to register for the webcast approximately 10 minutes before the start. A replay of the event will be made available from the Investor section of Zealand s website following the call. For further information, please contact: Britt Meelby Jensen, President and Chief Executive Officer Tel: , bmj@zealandpharma.com Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications Tel: , hlh@zealandpharma.com About Zealand Pharma Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ( Zealand ) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel investigational medicines and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. The company s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is licensed to Sanofi who markets the product globally (ex-us) as Lyxumia and has it under regulatory review in the US. The license agreement with Sanofi covers also LixiLan, which is the reference name for the fixed-ratio, singleproduct combination of lixisenatide and insulin glargine 100 Units/mL (Lantus ). LixiLan is under regulatory priority review by the US FDA and regulatory submission in the EU is planned by Sanofi for Q Zealand s proprietary pipeline includes: ZP4207 (a stable glucagon rescue treatment) for severe hypoglycemia in Phase II; ZP1848 for Short Bowel Syndrome in Phase II; ZP4207 (multiple-dose version) for better hypoglycemia management Zealand Pharma A/S 6/8
7 in diabetes in preparation for Phase II; ZP2929 for diabetes/obesity in Phase I; and several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand s business and activities, please visit: or follow us on Zealand Pharma A/S 7/8
8 GROUP KEY FIGURES DKK thousand INCOME STATEMENT AND COMPREHENSIVE INCOME Note Q4 Q4 Full year Full year Revenue 167,107 6, , ,773 Royalty expenses -19, ,267-13,776 Gross profit 147,566 5, , ,997 Research and development expenses -55,992-58, , ,036 Administrative expenses -16,606-19,244-44,606-39,826 Other operating income 2,041 3,972 12,828 6,328 Operating result 77,009-67,963-81,327-73,537 Net financial items -9,609-1,251-38,505 1,047 Result from ordinary activities before tax 67,400-69, ,832-72,490 Tax on ordinary activities 1 2,320 6,250 5,875 7,500 Net result for the period (after tax) 69,720-62, ,957-64,990 Comprehensive income for the period 69,720-62, ,957-64,990 Earnings per share - basic (DKK) 2, Earnings per share - diluted (DKK) 2, STATEMENT OF FINANCIAL POSITION 31 Dec 31 Dec Cash, cash restricted and cash equivalents 440, ,273 Total assets 634, ,756 Share capital ('000 shares) 24,353 23,193 Shareholder's equity 252, ,828 Equity/assets ratio Royalty bond 312, , CASH FLOW Q4 Q4 Full year Full year Depreciation 1,601 1,602 6,215 5,932 Change in working capital -122,211 25, ,871 15,521 Investments in fixed assets ,606-4,040-4,497 Free cash flow 2-46,366-38, ,373-46, OTHER 31 Dec 31 Dec Share price (DKK) Market capitalization (MDKK) 3,689 1,925 Equity per share (DKK) Average number of employees Products in clinical development (end period) Products in registration phase (end period) Medicines on the market 1 1 Notes: (1) According to Danish tax legislation Zealand is eligible to receive DKK 5.9 million in cash relating to the tax loss of 2015 (2) Free cash flow is calculated as cash flow from operating activities less purchase of property, plant and equipment (3) Equity per share is calculated as shareholders equity divided by total number of shares less treasury shares (4) In May 2015, Zealand initiated clinical Phase Ib development of ZP4207 for multiple dose use, and in September 2015, ZP1848 was advanced into clinical Phase II development (5) End of July 2015, Sanofi filed lixisenatide for regulatory approval in the US, and in September, the file was accepted for review by the FDA. In December 2015, Sanofi filed LixiLan for registration in the US. The file was accepted for review by the FDA in February 2016 Zealand Pharma A/S 8/8
Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress
Company Announcement No. 48 / 2015 Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress Lyxumia royalties and milestone
More informationFinancial results in line with expectations and important progress of the pipeline
Company Announcement - No. 37 / 2015 Zealand Interim report for H1 2015 (un-audited) Financial results in line with expectations and important progress of the pipeline Growing lixisenatide (Lyxumia ) royalty
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationAccelerating our business from peptides to patients
Accelerating our business from peptides to patients Jeffries Global Healthcare Conference London, 19 November 2015 Zealand Pharma A/S Disclaimer This presentation does not constitute or form part of and
More informationGROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR
ZEALAND GROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR US Roadshow June 2015 ZEALAND PHARMA DISCLAIMER This presentation does not constitute or form part of and should not be construed as, an offer
More informationFinancial statements for the year ending 31 December 2010
Company Announcement No. 02/2011 10 February 2011 For the full year 2010 Zealand Pharma generated revenue of DKK 87.4 (EUR 11.7) million, compared to DKK 25.3 (EUR 3.4) million in 2009, and recorded a
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationMaking a difference in patients lives
Making a difference in patients lives building a portfolio of metabolic and gastrointestinal medicines June 2017 1 Forward-looking statements This presentation contains information pertaining to Zealand
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationThe Dual Hormonal Artificial Pancreas in Diabetes Management. Medical Innovation Day Challenge
The Dual Hormonal Artificial Pancreas in Diabetes Management Medical Innovation Day Challenge 1 Background for the challenge A paradigm shift in treating diabetes Zealand Pharma is a Danish biotech company
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationAGENDA. Business highlights Significant progress with late stage clinical programs heading towards filing. Britt Meelby Jensen
AGENDA Business highlights Significant progress with late stage clinical programs heading towards filing The Zealand peptide platform World leading expertise delivering differentiated peptide-based drug
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationAstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.
[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationMaking a difference in patients lives
Making a difference in patients lives Building a portfolio of metabolic and gastrointestinal medicines March 2017 page 1 Forward-looking statements This presentation contains information pertaining to
More informationArgos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results
March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses
More informationNEWSLETTER June Summer greetings from Follicum
NEWSLETTER June 2018 Follicum hopes that this newsletter reaches as many of the company's owners and stakeholders as possible. If you wish to follow our continued development, please register your e-mail
More informationSumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,
More informationNewron announces 2018 financial results and provides outlook for 2019
Newron announces 2018 financial results and provides outlook for 2019 Milan, Italy, March 5, 2019 Newron Pharmaceuticals S.p.A. ( Newron ), a biopharmaceutical company focused on the development of novel
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationSlide 1. Investor presentation. Copenhagen 1 November 2018
Slide 1 Investor presentation Copenhagen 1 November 2018 Manato Shirley Ohara, Adelia Stewart diagnosed has type with 2 diabetes type 1 diabetes Kanagawa, New Orleans, Japan Louisiana, US Slide 2 Highlights
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationHILLENBRAND INDUSTRIES INC
HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationSmall-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationA leader in treating speciality gastrointestinal and metabolic diseases
A leader in treating speciality gastrointestinal and metabolic diseases Accelerating our late-stage pipeline 1 October 2018 Forward-looking statements This presentation contains information pertaining
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationTherapeutic products for respiratory and autoimmune diseases. Annual General Meeting
Therapeutic products for respiratory and autoimmune diseases Annual General Meeting November 2007 Summary Objective Lead products Discovery Listings Location Facility Employees Cash (30/6/07) Shares outstanding
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationVICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06
VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationSanthera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone
Santhera will hold a webcast tomorrow, November 21, 2018 at 13:00 CET, 12:00 GMT, 07:00 EST. Details at the end of statement. Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive
More informationEvofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data
More informationUnder the terms of the agreement, AVEO will receive an initial cash payment of $125 million, composed of a $75 million license fee and $50 million in
Astellas Pharma Inc. AVEO Pharmaceuticals Corporate Communications Investor Contact: Astellas Pharma Inc. Monique Allaire AVEO Pharmaceuticals +81(3)-3244-3201 (617) 299-5810 Media Contact: Dan Budwick
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationAstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma
AstraZeneca enhances long-term growth through Oncology investment in Acerta Pharma PUBLISHED17 December 2015Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationEiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results
Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationSunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights November 10, 2014 7:00 AM ET Announces Submission of Letter of Intent to File MAA for Vosaroxin in Relapsed or
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More informationAmylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes
Amylin Pharmaceuticals: Creating Value as a Leader in the Treatment of Diabetes Daniel M. Bradbury President & Chief Executive Officer JPMorgan Healthcare Conference January 12, 2009 Safe Harbor Statement
More informationLifeCycle Pharma A/S. 5 th Swiss-Scandinavian Bio-Business Seminar 2009 October 1, Peter Schøtt Knudsen, Head of IR & Legal
LifeCycle Pharma A/S 5 th Swiss-Scandinavian Bio-Business Seminar 2009 October 1, 2009 Peter Schøtt Knudsen, Head of IR & Legal FORWARD LOOKING STATEMENTS This presentation contains forward looking statements.
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationSlide 1. Investor Presentaton Jefferies Global Healthcare Conference. New York, 7 June Shanghai part of Cities Changing Diabetes
Slide 1 Investor Presentaton Jefferies Global Healthcare Conference New York, 7 June 2016 Shanghai part of Cities Changing Diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationEli Lilly and Company
Eli Lilly and Company Strategic Diabetes Alliance with Boehringer Ingelheim January 11 th, 2011 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's
More informationInvestor Presentation
ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an
More informationOncolytics Biotech Inc. Announces Third Quarter 2010 Results
November 10, 2010 Oncolytics Biotech Announces Third Quarter 2010 Results CALGARY, Nov. 10 /PRNewswire-FirstCall/ - Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced
More informationPIERIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPress Release. RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D
Press Release RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA Phase II Study for IBS-D Top-line results are expected in the third quarter of 2017 The randomized, double-blind, placebo-controlled
More information